
June 15 (Reuters) - Roche Holding AG ROG.S:
[AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR] ROCHE PROVIDES SAFETY UPDATE ON ELEVIDYS™ GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY IN NON-AMBULATORY PATIENTS
ROCHE HOLDING AG - PAUSES DOSING OF ELEVIDYS IN NON-AMBULATORY PATIENTS
ROCHE HOLDING AG - WORKING WITH HEALTH AUTHORITIES TO MODIFY PATIENT CARE
ROCHE HOLDING AG - DECISION FOLLOWS TWO CASES OF FATAL ACUTE LIVER FAILURE IN NON-AMBULATORY PATIENTS
ROCHE HOLDING AG - NEW DOSING RESTRICTIONS DO NOT IMPACT AMBULATORY DMD PATIENTS
ROCHE HOLDING AG - EUROPEAN REGULATORS REQUEST TEMPORARY CLINICAL HOLDS ON ELEVIDYS STUDIES